Atrial fibrillation primary prevention: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) (/* 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (DO NOT EDIT){{cite journal|last1=January|first1=C. T.|last2=Wann|first2=L. S.|last3=Alpert|first3=J. S.|last4=Calkins|first4=H.|last5=Cleveland|first5=J. C.|last6=Ci...) |
||
| Line 11: | Line 11: | ||
===Rhythm Control=== | ===Rhythm Control=== | ||
====Upstream Therapy==== | ====Pharmacological Agents for Preventing AF and Maintaining Sinus Rhythm==== | ||
=====Upstream Therapy===== | |||
{|class="wikitable" style="width: 80%;" | {|class="wikitable" style="width: 80%;" | ||
| Line 35: | Line 37: | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Statin]] therapy may be reasonable for primary prevention of new-onset [[AF]] after [[coronary artery]] surgery. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Statin]] therapy may be reasonable for primary prevention of new-onset [[AF]] after [[coronary artery]] surgery. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==Sources== | ==Sources== | ||
Revision as of 22:34, 31 March 2014
 |
Resident Survival Guide |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation primary prevention On the Web | |
|
Directions to Hospitals Treating Atrial fibrillation primary prevention | |
|
Risk calculators and risk factors for Atrial fibrillation primary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (DO NOT EDIT)[1]
Rhythm Control
Pharmacological Agents for Preventing AF and Maintaining Sinus Rhythm
Upstream Therapy
| Class III: No Benefit |
| "1. Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease. (Level of Evidence: B)" |
| Class IIa |
| "1. An ACE inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced LVEF. (Level of Evidence: B)" |
| Class IIb |
| "1. Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension. (Level of Evidence: B)" |
| "2. Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery. (Level of Evidence: A)" |
Sources
References
- ↑ 1.0 1.1 January, C. T.; Wann, L. S.; Alpert, J. S.; Calkins, H.; Cleveland, J. C.; Cigarroa, J. E.; Conti, J. B.; Ellinor, P. T.; Ezekowitz, M. D.; Field, M. E.; Murray, K. T.; Sacco, R. L.; Stevenson, W. G.; Tchou, P. J.; Tracy, C. M.; Yancy, C. W. (2014). "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society". Circulation. doi:10.1161/CIR.0000000000000041. ISSN 0009-7322.